• 1
    Krugman P. Bad for the country. New York Times, November 25, 2005.
  • 2
    Forrest S, Goetghebeur M, Hay J. Understanding the Underlying Drivers of Inpatient Cost Growth: a Literature Review. Am J Manag Care 2003;9(Suppl. 1):S313.
  • 3
    Thorpe KE, Florence CS, Joski P. Which medical conditions account for the rise in health care spending? Health Aff (Millwood) 2004. Jul–Dec; Suppl Web Exclusives:W4-437-45. Available from:[Accessed December 20, 2005].
  • 4
    Luce B, Mauskopf J, Sloan F, et al. The return on investment in health care: 1980–2000. Value Health 2006;9:146156.
  • 5
    Nordhaus W. The Health of Nations: The Contribution of Improved Health to Living Standards. NBER Working Paper Series 8818. Cambridge, MA: National Bureau of Economic Research, 2002.
  • 6
    Murphy KM, Topel RH, eds. Measuring the Gains from Medical Research: An Economic Approach. Chicago, IL: University of Chicago Press, 2003.
  • 7
    Lichtenberg FR. Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPS. Health Aff 2001;20:24151.
  • 8
    Cutler DM, McClellan M. Is technological change in medicine worth it? Health Aff 2001;20:1129.
  • 9
    U.S. Bureau of Labor Statistics. Tomorrow’s jobs. Available from:[Last accessed December, 2005].
  • 10
    Nationmaster Statistical Series. World exports of pharmaceutical preparations. Available from:[Last accessed December, 2005].
  • 11
    Bain Consultants. The trouble with cheap drugs. The Economist, January 29, 2004. Available from:[Last accessed July 2004].
  • 12
    Hay J. Chapter 14. Application of cost effectiveness and cost benefit analysis to pharmaceuticals. In: SantoroM, GorrieT, eds. The Grand Bargain: Ethics and the Pharmaceutical Industry in the 21st Century. New York: Cambridge University Press, 2005.